Cetus Corp. stock gained 12 percent on Thursday following thecompany's victory Wednesday in its PCR patent infringementsuit against Du Pont. The stock rose $1.38, closing at $12.75.Cetus' stock (NASDAQ:CTUS) has only partially recovered fromits dramatic plunge last summer after a Food and DrugAdministration committee failed to recommend marketingapproval for interleukin-2. Within the past year, Cetus, ofEmeryville, Calif., has traded as high as $22.50 a share and aslow as $5.63.
Amgen Corp. (NASDAQ:AMGN) closed down $2 at $91.25, asinvestors continued to take profits. Amgen, of Thousand Oaks,Calif., last Friday hit a high of $105.25 after the FDA approvedNeupogen, its granulocyte colony stimulating factor.
(c) 1997 American Health Consultants. All rights reserved.